Home Medicine Recurrent Painful Calcium Pyrophosphate Arthropathy
Article Open Access

Recurrent Painful Calcium Pyrophosphate Arthropathy

  • Lisa Carpenter , Noelle Juliano and Ronald Herb
Published/Copyright: March 1, 2017

Keywords: calcium pyrophosphate arthropathy, calcium pyrophosphate crystals, calcium pyrophosphate deposition disease

A 69-year-old woman presented to her primary care physician with pain and decreased range of motion in her left knee for the past 5 days. She reported no history of trauma. The patient underwent an arthrocentesis and received a 1.5-mL injection of triamcinolone, which improved her pain and range of motion. She returned 9 months later with the same symptoms lasting for 3 days. Physical examination revealed decreased flexion and extension and fullness in the posterior joint space. Laboratory studies revealed a high erythrocyte sedimentation rate (63 mm/h) and C-reactive protein level (7.66 mg/dL). Plain film radiograph of the knee showed calcification in the popliteal fossa (image). Calcium pyrophosphate crystals were identified in the synovial fluid, and calcium pyrophosphate deposition disease was diagnosed. She was given a 1.2-mg dose of colchicine orally, followed by a 0.6-mg dose 6 hours later, which resolved her symptoms and improved her range of motion.

Deposition of calcium pyrophosphate crystals into joint spaces can lead to severe, chronic arthritic attacks and damage to the cartilage.1 The most common management of localized symptoms is corticosteroid injection. Oral methods include colchicine and nonsteroidal anti-inflammatory drugs.2 Colchicine can also be used prophylactically. Methotrexate and anakinra have been used for management, but recent studies suggest they provide no notable effect.2,3


From the Department of Internal Medicine at the Reading Health System in West Reading, Pennsylvania.
Dr Carpenter is a third-year resident and Dr Juliano is a second-year resident.

*Address correspondence to Lisa Carpenter, DO, Reading Hospital, Department of Internal Medicine, 420 S 5th Ave, West Reading, PA 19611-2143. E-mail:


References

1. Rosenthal AK , RyanLM. Calcium pyrophosphate deposition disease. N Engl J Med . 2016;374(26):2575-2584. doi:10.1056/NEJMra151111710.1056/NEJMra1511117Search in Google Scholar PubMed PubMed Central

2. Finckh A , Mc CarthyGM, MadiganA, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther . 2014;16(5):458. doi:10.1186/s13075-014-0458-410.1186/s13075-014-0458-4Search in Google Scholar PubMed PubMed Central

3. Ottaviani S , BrunierL, SibilaJ, et al. Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine . 2013;80(2):178-182. doi:10.1016/j.jbspin.2012.07.01810.1016/j.jbspin.2012.07.018Search in Google Scholar PubMed

Received: 2016-06-30
Accepted: 2016-07-14
Published Online: 2017-03-01
Published in Print: 2017-03-01

© 2017 American Osteopathic Association

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloaded on 5.12.2025 from https://www.degruyterbrill.com/document/doi/10.7556/jaoa.2017.036/html
Scroll to top button